导航
| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -3.68% | 3154/4773 |
| 近一周 | -2.14% | 1313/5462 |
| 近一月 | -4.24% | 2323/5421 |
| 近一季 | -7.26% | 2347/5209 |
| 近半年 | -0.56% | 1333/4920 |
| 近一年 | -1.90% | 2940/4366 |
| 近两年 | 36.07% | 2052/2954 |
| 近三年 | 24.61% | 1294/2253 |
| 成立以来 | 86.65% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-4.70% 3674/4961 |
8.84% 2531/5312 |
- - |
- - |
| 2025 | 16.67% 2426/4813 |
-1.05% 2558/3635 |
2.47% 1546/4076 |
12.91% 3031/4524 |
1.90% 1162/4813 |
| 2024 | 20.24% 477/3463 |
4.80% 430/2808 |
0.52% 587/3014 |
17.89% 1105/3129 |
-3.19% 2284/3463 |
| 2023 | -9.27% 1142/2656 |
1.28% 1602/2280 |
-4.43% 1167/2385 |
1.08% 321/2515 |
-7.26% 2105/2655 |
| 2022 | -14.71% 386/2207 |
-12.21% 590/1919 |
8.91% 317/2016 |
-12.56% 728/2113 |
2.03% 1062/2208 |
| 2021 | -3.99% 936/1822 |
-3.06% 750/1255 |
6.38% 755/1330 |
-8.24% 1116/1466 |
1.47% 924/1822 |
| 2020 | 37.70% 376/1250 |
-10.07% 746/1028 |
17.56% 369/1067 |
10.92% 496/1164 |
17.43% 125/1184 |
| 2019 | 34.29% 408/1092 |
16.75% 663/754 |
4.78% 20/804 |
1.50% 395/850 |
8.16% 347/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 汇安富时中国A50ETF VS. 长安沪深300非周期A(740101) |